Regeneron Pharmaceuticals (REGN)

Apr 18, 2025, 11:15 AM EDT - 2 days ago

Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Apr 18, 2025, 11:15 AM EDT - 2 days ago

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Apr 16, 2025, 3:57 AM EDT - 5 days ago

Regeneron: Still A Biotech Juggernaut

Apr 14, 2025, 2:03 PM EDT - 6 days ago

Trump Says Pharmaceutical Tariffs Coming in Near Future

Apr 14, 2025, 12:26 PM EDT - 6 days ago

Trump says US pharma tariffs coming in not-too-distant future

Apr 11, 2025, 10:30 AM EDT - 9 days ago

Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages

Apr 10, 2025, 4:45 AM EDT - 11 days ago

Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback

Apr 9, 2025, 6:32 PM EDT - 11 days ago

BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks

Apr 9, 2025, 3:59 PM EDT - 11 days ago

Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out

Apr 9, 2025, 2:27 PM EDT - 11 days ago

Explainer: Prescription drugs become a target in Trump's trade war

Apr 9, 2025, 1:06 PM EDT - 11 days ago

Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'

Apr 9, 2025, 11:53 AM EDT - 11 days ago

Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs

Apr 9, 2025, 11:51 AM EDT - 11 days ago

Pharmaceutical stocks fall as Trump doubles down on tariffs threat

LLY ABBV AMGN AZN BMY GSK JNJ

Apr 6, 2025, 2:36 AM EDT - 15 days ago

Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow

Apr 1, 2025, 9:34 AM EDT - 19 days ago

RFK Jr. 'needs a lot of help and expertise' on science, says Regeneron CEO

Apr 1, 2025, 8:23 AM EDT - 19 days ago

Regeneron CEO Leonard Schleifer on tariffs: Let's make sure the Europeans pay their fair share

Mar 28, 2025, 2:00 AM EDT - 24 days ago

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

Mar 28, 2025, 2:00 AM EDT - 24 days ago

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Mar 25, 2025, 4:05 PM EDT - 26 days ago

Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025

Mar 24, 2025, 11:13 PM EDT - 27 days ago

Lawsuit Notice: Investors who hold Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares should contact the Shareholders Foundation

Mar 14, 2025, 9:40 AM EDT - 5 weeks ago

Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?

Mar 11, 2025, 10:50 PM EDT - 5 weeks ago

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem

Mar 11, 2025, 9:32 PM EDT - 5 weeks ago

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem

Mar 11, 2025, 10:25 AM EDT - 5 weeks ago

Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners 2025 Global Healthcare Conference Call Transcript

Mar 8, 2025, 1:00 PM EST - 6 weeks ago

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD